Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Power of Prescription Drug Monitoring Programs (PDMP) in an American Health Crisis

A 2010 national youth drug abuse study revealed some disturbing results. In 2009, the drugs of choice for 6 of 10 drug abusers in the 12th grade were prescription pharmaceuticals. Likewise, data from a 2008 SAMSHA report revealed that the previous decade had seen a four-fold increase in the number of those seeking treatment for addiction…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

A 2010 national youth drug abuse study revealed some disturbing results. In 2009, the drugs of choice for 6 of 10 drug abusers in the 12th grade were prescription pharmaceuticals. Likewise, data from a 2008 SAMSHA report revealed that the previous decade had seen a four-fold increase in the number of those seeking treatment for addiction to prescription painkillers. In response to the serious public health problem in this country, efforts are underway to combat this growing threat. One solution is the advent of Prescription Drug Monitoring Programs (PDMP).

What is a PDMP?

PDMP is a healthcare tool with a variety of applications. The first PDMP appeared in California in 1939, primarily as a benefit for law enforcement tracking illegal drug behaviors. Today’s PDMP has evolved; as an online database of prescribing and dispensing data, PDMP helps identify when a patient obtains multiple prescriptions from different practitioners. Each database is state-run and used to address prescription drug diversion and abuse. PDMPs serve multiple functions. A PDMP is a patient care tool, a drug epidemic early warning system, and a drug diversion and insurance fraud investigation mechanism. The goal of the PDMP is to reduce the impact of prescription drug abuse and diversion.

Areas of Current and Future PDMP Impact

Not all states have PDMP requirements. Those who currently require health care personnel to utilize this system are Arizona, Connecticut, Maine, Minnesota, New York, Virginia, North Carolina, and Rhode Island. These states are seeing drastically reduced incidences of fraudulent patient behavior.

This is especially true in highly populated states such as New York, where improved visibility into prescribing patterns and potential drug-seeking behaviors has been critical to combating the practice of “doctor shopping,” as described above, in which drug addicts and system abusers go from clinic to clinic amassing a pile of prescriptions for the desired controlled substances. Looking toward the future, 12 states have requirements pending, and the hope is that the 29 states plus DC and Guam who currently have no requirement will decide to follow suit soon.

New York’s successful program has expanded to include access to other state databases and information, and this transparency and interoperability might be a prediction of the future of PDMP.

Overall Benefits

Data regarding PDMP use by state clearly shows positive benefits in the states that use these tools. While research into PDMP effectiveness is ongoing, a 2012 study looked at rates of painkiller abuse and misuse in PDMP vs. non-PDMP states from 2003 to 2009 and discovered that in non-PDMP states, rates of abuse and misuse increased more rapidly than in states with such programs.

But PDMPs are not just concerned with legality. Hand-in-hand with reduced fraudulent and abusive behavior is the improvement of identification of and treatment options for those spiraling in the tornado of the addiction epidemic, perhaps the real crowning achievement of these programs. A hallmark of addiction is a lack of self-awareness and honesty regarding one’s own harmful behaviors, and the PDMP becomes a life-saving tool in which doctors and patients can have the transparent conversations needed to kick-start recovery.

DrFirst and ChartLogic

DrFirst has been at the forefront of electronic prescribing of controlled substances (EPCS) since it sent the nation’s first electronic prescription of a controlled substance. In our partnership with DrFirst, ChartLogic is poised to make a huge impact on this current health crisis as part of a joint effort. The marriage of our software with DrFirst’s program makes sense given the proven success of our ambulatory EHR suite that includes Electronic Medical Records, Practice Management, and Billing Services. And we are proud to be part of a solution that is not only changing lives, but also saving them

Read more at chartlogic.com

Sources:

http://www.chartlogic.com/blog/the-power-of-prescription-drug-monitoring-programs/#_ednref1

https://www.ncjrs.gov/pdffiles1/ondcp/pdmp.pdf

https://searchandrescueusa.org/monitoryourpatients/?utm_source=google&utm_medium=ppc&utm_campaign=2018_PFDK_Nonbrand_PDMP&utm_term=pdmp

https://healthitanalytics.com/news/ny-expands-prescription-drug-monitoring-program-to-25-states

https://www.drugrehab.org/the-benefits-of-prescription-drug-monitoring-programs-pdmp/

https://www.drfirst.com/resources/e-prescribing-mandate-map/

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512